ArticleNature medicine2025
Autologous T cell therapy for PRAME
Erratum issuedAbstract readClinical Trial, Phase IMulticenter Study
In one paragraph
Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- Reprogramming engineered autologous T cells to overcome resistance in patients with Merkel cell carcinoma.Science translational medicine · 2026Trial
- The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions.Human vaccines & immunotherapeutics · 2026Review
- Current status and challenges of TCR-T cell therapy for AML/MDS.International journal of hematology · 2026Review
- Review
- Receptor-defined targeting of a genomically unique melanoma-enriched noncanonical antigen.Signal transduction and targeted therapy · 2026Article
- Emerging frontiers in adoptive cell therapies: engineering innovations, current challenges, and manufacturing perspectives.Molecular biology reports · 2026Review
- Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies.Experimental hematology & oncology · 2026Review
- PRAME promotes invasion and metastasis of salivary adenoid cystic carcinoma by regulating RARα stability via the cullin2 ubiquitin-proteasome system.Clinical and translational medicine · 2026Article
- mRNA-based immunotherapy improves the efficacy of adoptively transferred TCR transgenic T cells in a murine solid tumour model.Scientific reports · 2026Article
- MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.Nature medicine · 2026Article
- Advances in cancer immunotherapy: adoptive cell therapy and immune cell engagers in solid tumours.British journal of cancer · 2026Review
- Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells.Signal transduction and targeted therapy · 2026Review
- Cellular immunotherapy in melanoma: the next frontier in cancer treatment.Journal of experimental & clinical cancer research : CR · 2026Review
- [Therapy of melanoma : Current standards and future perspectives].Pathologie (Heidelberg, Germany) · 2026Review
- Circumventing IFN-γ induced resistance in ovarian cancer with a double-hit: NKG2A knockout of PRAME-TCR expressing NK cells.Journal of ovarian research · 2026Article
- Hallmarks and correlates of effective adoptive cell immunotherapy for cancer.Nature reviews. Immunology · 2026Review
- Recent advances in the molecular genetic mechanisms and immune microenvironment of uveal melanoma.Melanoma research · 2026Review
- A generalizable system for antigenic peptide targeting across HLA-I allotypes.bioRxiv : the preprint server for biology · 2026Article
- Systemic Therapy for Solitary Fibrous Tumor.Current treatment options in oncology · 2026Review
- Advances in cell therapy for solid tumours: European perspective and future directions.The Lancet regional health. Europe · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
40 authors.
Martin WermkeDepartment of Medicine I, University Hospital Carl Gustav Carus TU Dresden, Dresden, Germany.ORCID http://orcid.org/0000-0002-4844-4087
Dejka M AraujoDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Manik ChatterjeeComprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.
Apostolia M TsimberidouDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tobias A W HolderriedDepartment of Hematology, Oncology, Immunooncology, Stem Cell Transplantation, and Rheumatology, University Hospital Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0002-2474-523X
Amir A JazaeriDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-4335-4151
Ran ReshefColumbia University Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-2185-9546
Carsten BokemeyerDepartment of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Winfried AlsdorfDepartment of Oncology, Hematology, and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0002-3018-2437
Katrin WetzkoDepartment of Medicine I, University Hospital Carl Gustav Carus TU Dresden, Dresden, Germany.
Peter BrossartDepartment of Hematology, Oncology, Immunooncology, Stem Cell Transplantation, and Rheumatology, University Hospital Bonn, Bonn, Germany.
Katrin AslanImmatics Biotechnologies GmbH, Tübingen, Germany.
Linus BackertImmatics Biotechnologies GmbH, Tübingen, Germany.
Sebastian BunkImmatics Biotechnologies GmbH, Tübingen, Germany.
Jens FritscheImmatics Biotechnologies GmbH, Tübingen, Germany.ORCID http://orcid.org/0000-0002-5557-8577
Swapna GuldeImmatics Biotechnologies GmbH, Tübingen, Germany.
Silvana HenglerImmatics Biotechnologies GmbH, Tübingen, Germany.ORCID http://orcid.org/0000-0001-6973-0800
Norbert HilfImmatics Biotechnologies GmbH, Tübingen, Germany.ORCID http://orcid.org/0000-0002-2618-8174
Mohammad B HossainImmatics US, Inc., Houston, TX, USA.
Jens HukelmannImmatics Biotechnologies GmbH, Tübingen, Germany.
Mamta KalraImmatics US, Inc., Houston, TX, USA.
Delfi KrishnaImmatics US, Inc., Houston, TX, USA.
M Alper KursunelImmatics Biotechnologies GmbH, Tübingen, Germany.
Dominik MaurerImmatics Biotechnologies GmbH, Tübingen, Germany.
Andrea Mayer-MoklerImmatics Biotechnologies GmbH, Tübingen, Germany.
Regina MendrzykImmatics Biotechnologies GmbH, Tübingen, Germany.
Ali MohamedImmatics US, Inc., Houston, TX, USA.
Karine PozoImmatics US, Inc., Houston, TX, USA.
Arun SatelliImmatics US, Inc., Houston, TX, USA.
Marilena LetiziaImmatics Biotechnologies GmbH, Tübingen, Germany.
Heiko SchusterImmatics Biotechnologies GmbH, Tübingen, Germany.
Oliver SchoorImmatics Biotechnologies GmbH, Tübingen, Germany.
Claudia WagnerImmatics Biotechnologies GmbH, Tübingen, Germany.
Hans-Georg RammenseeInstitute of Immunology, Eberhard Karls University Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0003-1614-2647
Carsten ReinhardtImmatics Biotechnologies GmbH, Tübingen, Germany.
Harpreet Singh-JasujaImmatics Biotechnologies GmbH, Tübingen, Germany.
Steffen WalterImmatics US, Inc., Houston, TX, USA.
Toni WeinschenkImmatics Biotechnologies GmbH, Tübingen, Germany.
Jason J Luke *Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-1182-4908
Cedrik M Britten *Immatics Biotechnologies GmbH, Tübingen, Germany. cedrik.britten@immatics.com.ORCID http://orcid.org/0000-0003-3424-8760
Funding
ZACOPRIDE VS METOCLOPRAMIDE--EFFECT ON LOWER ESOPHAGEAL SPHINCTERM01RR000847 · NCRR · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI ALTES, TALISSA A · 1985 to 2010
$48.1MDevelopment of the MasSpec Pen Technology to Guide Surgical Decisions in the Care for Patients with Ovarian CancerR01CA306089 · NCI · BAYLOR COLLEGE OF MEDICINE · PI AMIR A JAZAERI, ANIL K SOOD · 2025 to 2026
$1.4MCancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) DP150029NCI NIH HHS L30 CA123720NCI NIH HHS R01 CA306089NCRR NIH HHS M01 RR000847
Abstract
In contrast to chimeric antigen receptor T cells, T cell receptor (TCR)-engineered T cells can target intracellular tumor-associated antigens crucial for treating solid tumors. However, most trials published so far show limited clinical activity. Here we report interim data from a first-in-human, multicenter, open-label, 3 + 3 dose-escalation/de-escalation phase 1 trial studying IMA203, an autologous preferentially expressed antigen in melanoma (PRAME)-directed TCR T cell therapy in HLA-A*02
Indexed as
Antigens, NeoplasmHLA-A2 AntigenImmunotherapy, AdoptiveMelanomaNeoplasmsSarcomaT-LymphocytesAdultAgedFemaleHumansMaleMaximum Tolerated DoseMiddle AgedReceptors, Antigen, T-CellTransplantation, AutologousAntigens, NeoplasmHLA-A*02 antigenHLA-A2 AntigenPRAME protein, humanReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.